跳到正文
原文
FiercePharma· @FiercePharma · X·· 14 天前AI 评分42
AI 导读

拜耳的制药业务或许终于要进入增长周期了,但CEO Bill Anderson仍然无法完全摆脱围绕潜在业务拆分的质疑。

正文

Bayer’s pharma business may finally be entering a growth cycle, but CEO Bill Anderson still can’t quite escape questions around a potential business split. https://www.fiercepharma.com/pharma/bayer-spots-pharma-recovery-questions-resurface-over-potential-crop-science-split

来源:FiercePharma · x.com